Highlights
- •We describe a case of relapsing tumefactive demyelinating disease with long follow-up.
- •We emphasize that relapsing tumefactive demyelinating lesions can occur without other signs of multiple sclerosis.
- •This is an aggressive condition that can be unresponsive to immunotherapy.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Journal of the Neurological SciencesAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Tumefactive demyelination: an approach to diagnosis and management.J Neurol Neurosurg Psychiatry. 2013; 84: 1047-1053
- Importance of radiotherapy in the outcome of patients with primary CNS lymphoma: an analysis of the CHOD/BVAM regimen followed by two different radiotherapy treatments.J Clin Oncol. 2002; 20: 231-236
- Antibodies to MOG and AQP4 in adults with neuromyelitis optica and suspected limited forms of the disease.Mult Scler. Oct 24 2014; ([Epub ahead of print, pii:1352458514555785])
- Characteristic neuroimaging in patients with tumefactive demyelinating lesions exceeding 30 mm.J Neuroimaging. 2011; 21: e69-e77
- Current role of chemotherapy and bone marrow transplantation in multiple sclerosis.Curr Treat Options Neurol. 2015; 17: 324
- Favourable response to plasma exchange in tumefactive CNS demyelination with delayed B-cell response.Mult Scler. 2012; 18: 1045-1049
Article info
Publication history
Published online: March 30, 2015
Accepted:
March 24,
2015
Received in revised form:
March 2,
2015
Received:
January 28,
2015
Identification
Copyright
© 2015 Elsevier B.V. Published by Elsevier Inc. All rights reserved.
